EAT is up +49.38%% since April’24 pick View All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 502 days ( 76.30 % )
Last Price $0.0830 0 %
High/ Low $0.0830 - $0.0830 0%
Chg 7 Days N/A $0.0830 $0.0830
Chg 30 Days -5.46 % $0.0878 $0.0830
Chg 12 mos -9.13 % $0.0913 $0.0830
Trend - 3 mos 54.57 % Width: 36.31 %
Trend - 12 mos -30.72 % Width: 299.32 %
Pred. range - 3 mos $0.118 - $0.161 42.50 % - 94.23 %
Pred. range - 12 mos $0.0169 - $0.0675 -79.61 % - -18.58 %
Short MA avg 3 mos Buy May 30, 2024 - 18 days
Long MA avg 3 mos Buy May 03, 2024 - 36 days
Short/Long MA avg 3 mos Buy May 06, 2024 - 35 days
Short MA avg 12 mos Buy Jun 20, 2024 - 4 days
Long MA avg 12 mos Buy May 03, 2024 - 36 days
Short/Long MA avg 12 mos Buy May 10, 2024 - 31 days
Pivot Short Sell Jun 21, 2024 - 3 days
Bollinger Sell Nov 30, -1 - N/A days
MACD Sell No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Synairgen plc

Synairgen plc Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic ... SYGGF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT